Dr. Puhlmann has worked in oncology drug development for 20 years, and worked as the franchise head of global clinic development at Seagen. He also held positions with Merck & Co, Schering Plough, Bayer and Amgen and the National Cancer Institute.
“The opportunity to lead the development of Viewpoint’s pipeline programs is extremely exciting for me as a cancer drug developer. I think the application of targeted alpha-particle therapy will have a profound impact on the treatment of oncology patients,” Dr. Puhlmann said in an Oct. 4 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
